8 http://www.fda.gov/NewsEvents/Newsroom/PressAnnounce- ments/ucm230241.htm. [3] European Medicines Agency, “Pradaxa’s approval for use in European Union,” 2011, http://www.ema.europa.eu/ema/ index.jsp?curl=pages/medicines/human/medicines/000829/ human med 000981.jsp&mid=WC0b01ac058001d124. [4] J. J. You, D. Singer, P. A. Howard et al., “Antithrombotic therapy for atrial ﬁbrillation: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines,” Chest, vol. 141, supplement 2, pp. e531S–e575S, 2012. [5] J. Pink, S. Lane, M. Pirmohamed, and D. A. Hughes, “Dabigatran etexilate versus warfarin in management of non- valvular atrial ﬁbrillation in UK context: quantitative beneﬁt- harm and economic analyses,” British Medical Journal, vol. 343, Article ID d6333, pp. 1–14, 2011. [6] C. J. L. Murray and A. D. Lopez, “Mortality by cause for eight regions of the world: global burden of disease study,” The Lancet, vol. 349, no. 9061, pp. 1269–1276, 1997. [7] C. Sarti, D. Rastenyte, Z. Cepaitis, and J. Tuomilehto, “Inter- national trends in mortality from stroke, 1968 to 1994,” Stroke, vol. 31, no. 7, pp. 1588–1601, 2000. [8] D.-G. da Saude, “Risco de morrer em Portugal 2006—vol. 1 (In Portuguese),” Direcc¸a˜o-Geral da Sau´ de, Direcc¸a˜o de Servic¸os de Epidemiologia e Estat´ısticas de Sau´ de, Divisa˜o de Epidemiologia, Lisboa, 2009, http://www.dgs.pt. [9] M. Correia, M. R. Silva, I. Matos et al., “Prospective community-based study of stroke in Northern Portugal: incidence and case fatality in rural and urban populations,” Stroke, vol. 35, no. 9, pp. 2048–2053, 2004. [10] D. Bonhorst, M. Mendes, P. Adraga˜o et al., “Prevalence of atrial ﬁbrillation in the Portuguese population aged 40 and over: the FAMA study,” Revista Portuguesa de Cardiologia, vol. 29, no. 3, pp. 331–350, 2010. [11] L. Guize, F. Thomas, K. Bean, A. Benetos, and B. Pannier, “Atrial ﬁbrillation: prevalence, risk factors and mortality in a large French population with 15 years of follow-up,” Bulletin de l’Academie Nationale de Medecine, vol. 191, no. 4-5, pp. 791–805, 2007. [12] N. F. Murphy, C. R. Simpson, P. S. Jhund et al., “A national survey of the prevalence, incidence, primary care burden and treatment of atrial ﬁbrillation in Scotland,” Heart, vol. 93, no. 5, pp. 606–612, 2007. [13] D. Deplanque, D. Leys, L. Parnetti et al., “Stroke prevention and atrial ﬁbrillation: reasons leading to an inappropriate management: main results of the SAFE II study,” British Journal of Clinical Pharmacology, vol. 57, no. 6, pp. 798–806, 2004. [14] A. J. Camm, P. Kirchhof, G. Y. Lip et al., “Guidelines for the management of atrial ﬁbrillation: the task force for the management of atrial ﬁbrillation of the European Society of Cardiology (ESC),” European Heart Journal, vol. 31, pp. 2369– 2429, 2010. [15] European Medicines Agency, “Updates on safety of Prad- axa,” 2011, http://www.ema.europa.eu/ema/index.jsp?curl= pages/news and events/news/2011/11/news detail 001390.jsp &mid=WC0b01ac058004d5c1&jsenabled=true. [16] D. W. Cockcroft and M. H. Gault, “Prediction of creatinine clearance from serum creatinine,” Nephron, vol. 16, no. 1, pp. 31–41, 1976. [17] European Medicines Agency. Pradaxa, “Summary of Product Characteristics,” 2011, http://www.ema.europa.eu/docs/en GB/document library/EPAR - Product Information/human/ 000829/WC500041059.pdf. Thrombosis [18] L. Wallentin, S. Yusuf, M. D. Ezekowitz et al., “Eﬃcacy and safety of dabigatran compared with warfarin at diﬀerent levels of international normalised ratio control for stroke prevention in atrial ﬁbrillation: an analysis of the RE-LY trial,” The Lancet, vol. 376, no. 9745, pp. 975–983, 2010. [19] S. A. Doggrell, “Adherence to medicines in the older-aged with chronic conditions: does intervention by an allied health professional help?” Drugs & Aging, vol. 27, no. 3, pp. 239–254, 2010. [20] S. Noble and K. L. Goa, “Ticlopidine: a review of its pharma- cology, clinical eﬃcacy and tolerability in the prevention of cerebral ischaemia and stroke,” Drugs & Aging, vol. 8, no. 3, pp. 214–232, 1996. [21] J. Aisenberg, S. J. Connolly, S. Yang et al., “Upper gastrointesti- nal symptoms occurring in dabigatran—treated subjects: an analysis of the RE-LY trial with 18,113 subjects,” in Proceedings of the American College of Gastroenterology Annual Scientiﬁc Meeting, Washington, DC, USA, October 2011. [22] G. J. Hankey and J. W. Eikelboom, “Dabigatran etexilate: a new oral thrombin inhibitor,” Circulation, vol. 123, no. 13, pp. 1436–1450, 2011. [23] J. van Ryn, J. Stangier, S. Haertter et al., “Dabigatran etexilate—a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagu- lant activity,” Thrombosis and Haemostasis, vol. 103, no. 6, pp. 1116–1127, 2010. [24] M. V. Huisman, G. Y. H. Lip, H. C. Diener et al., “Dabigatran etexilate for stroke prevention in patients with atrial ﬁbrilla- tion: resolving uncertainties in routine practice,” Thrombosis and Haemostasis, vol. 107, no. 5, 2012. [25] J. Stangier, H. Sta¨hle, K. Rathgen, and R. Fuhr, “Pharmacoki- netics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects,” Clinical Pharmacokinetics, vol. 47, no. 1, pp. 47–59, 2008. [26] Boehringer Ingelheim, “Pradaxa (dabigatran etexilate) Pre- scriber guide for stroke prevention in atrial ﬁbrillation,” 2011, http://www.pradaxa.co.uk/downloads/spaf-prescriber-guide .pdf. [27] C. E. DeRemer, J. S. Gujral, J. W. Thornton, and R. A. Sorrentino, “Dabigatran falsely elevates point of care inter- national normalized ratio results,” The American Journal of Medicine, vol. 124, pp. e5–e6, 2011. [28] J. van Ryn, T. Litzenburger, A. Waterman et al., “Dabigatran anticoagulant activity is safely neutralized by an antibody selective to dabigatran in vitro and in vivo models,” Journal of American College of Cardiology, vol. 57, no. 14, p. E-1130, 2011. [29] I. Pragstl, B. Do¨rr, F. Kaspereit et al., “Beriplex P/N reverses bleeding in an acute renal injury model after dabigatran overdose in rabbits,” Pathophysiology of Haemostasis and Thrombosis, vol. 37, pp. A94–P486, 2010. [30] J. van Ryn, D. Ruhl, H. Priepke et al., “Reversibility of the anticoagulant eﬀect of high doses of the direct thrombin inhibitor, dabigatran, by recombinant factor VIIa or activated prothrombin complex concentrate,” Haematologica, vol. 93, supplement 1, p. 148, 2008, abstract 0370. [31] E. S. Eerenberg, P. W. Kamphuisen, M. K. Sijpkens et al., “Reversal pf rivaroxaban and dabigatran by prothrom- bin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects,” Circulation, vol. 124, pp. 1573–1579, 2011. [32] F. Wagner, H. Peters, S. Formella et al., “Eﬀective elimination of dabigatran with haemodialysis: a phase-I single-centre